Drug developers are still hunting for surrogate end points that can better capture the benefits of checkpoint inhibitors, oncolytic viruses and modified T cell therapies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
Nature Communications Open Access 22 October 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Dolgin, E. Cancer immunology community seeks better end points. Nat Rev Drug Discov 15, 808–809 (2016). https://doi.org/10.1038/nrd.2016.254
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2016.254
This article is cited by
-
Oncolytic adenovirus programmed by synthetic gene circuit for cancer immunotherapy
Nature Communications (2019)
-
Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer
Clinical and Translational Oncology (2019)
